In a Placebo-Controlled 36-Week Phase 2 Trial, Treatment with Mgl-3196 Compared to Placebo Results in Significant Reductions in Hepatic Fat (MRI-PDFF), Liver Enzymes, Fibrosis Biomarkers, Atherogenic Lipids, and Improvement in Nash on Serial Liver Biopsy

Published

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Harrison, SA; Guy, CD; Bashir, M; Frias, JP; Alkhouri, N; Baum, S; Taub, RA; Moylan, CA; Bansal, MB; Neuschwander-Tetri, BA; Moussa, S

Published Date

  • October 1, 2018

Published In

Volume / Issue

  • 68 /

Start / End Page

  • 9A - 10A

Published By

Pages

  • 2

Electronic International Standard Serial Number (EISSN)

  • 1527-3350

International Standard Serial Number (ISSN)

  • 0270-9139

Conference Name

  • Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting

Conference Location

  • San Francisco, CA

Conference Start Date

  • November 9, 2018

Conference End Date

  • November 13, 2018